Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome

Neoadjuvant imatinib therapy has been proposed for routine practice with favorable long-term results for patients with locally advanced gastrointestinal stromal tumors (GISTs). However, clarification of the optimal duration, safety, and oncological outcomes of neoadjuvant imatinib use before surgica...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2019-03, Vol.11 (3), p.424
Main Authors: Wang, Shang-Yu, Wu, Chiao-En, Lai, Chun-Chi, Chen, Jen-Shi, Tsai, Chun-Yi, Cheng, Chi-Tung, Yeh, Ta-Sen, Yeh, Chun-Nan
Format: Article
Language:English
Subjects:
Atrophy
Computed tomography
Esophagus
Gastrointestinal surgery
Ileum
Imatinib
Jejunum
Laparoscopy
Laparotomy
Literature reviews
Medical imaging
Mutation
Patients
Rectum
Stomach
Surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neoadjuvant imatinib therapy has been proposed for routine practice with favorable long-term results for patients with locally advanced gastrointestinal stromal tumors (GISTs). However, clarification of the optimal duration, safety, and oncological outcomes of neoadjuvant imatinib use before surgical intervention remains necessary. We prospectively analyzed the treatment outcomes of 51 patients with locally advanced, nonmetastatic GISTs treated with neoadjuvant imatinib followed by surgery. The optimal duration was defined as the timepoint when there was a
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers11030424